Phototherapy for Non-responders to Oral Appliance Therapy for Obstructive Sleep Apnea
NCT06960200
Recruiting
Obstructive sleep apnea (OSA) is a medical condition where a person has great difficulty with breathing, or stops breathing all together, while asleep. This is a medical condition for which one of the current standard treatments is the use of a custom made dental appliance to help hold the person's airway open while asleep so that the person does not suffocate while sleeping. However, while the majority of OSA patients are able to tolerate the use of oral appliance therapy (OAT) for OSA, some pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Alberta, Edmonton, Alberta T6G 2E1, Edmonton, Not set
Conditions: Obstructive Sleep Apnea
Register for Updates
Exploring the Use of Phototherapy to Improve CPAP Compliance
NCT06960161
Recruiting
Photobiomodulation (PBM) is a type of light therapy like lasers and LEDs. PBM was previously known by different terms like "low-level laser therapy" (LLLT) or "photobiostimulation." LLLT, despite its name, can also have effects beyond biomodulation, including thermal effects useful in medical imaging and therapy. PBM works by interacting with our biological systems, and its clinical benefits depend on factors like light wavelength, and energy output. PBM has various clinical applications, such... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Enjoy Dental, Edmonton, Alberta
Conditions: Obstructive Sleep Apnea
Register for Updates
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Clinical Trial Site, Birmingham, Alabama +39 locations
Conditions: Generalized Myasthenia Gravis
Register for Updates
Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada
NCT06960291
Recruiting
EXCEL will provide online and, where feasible, in-person exercise programs to individuals living with and beyond cancer (ILWBC). Research has shown that targeted programs that include tailored exercise prescriptions are more successful in helping individuals with chronic disease to incorporate physical activity and exercise into their daily routines. While ILWBC are advised by healthcare professionals (HCPs) to engage in exercise, there is a lack of cancer-specific exercise programs and cancer-t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Calgary, Calgary, Alberta +4 locations
Conditions: Cancer, Prostate Cancers, Breast Cancers, Colon Cancer, Lung Cancers
Register for Updates
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Recruiting
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +18 locations
Conditions: Multiple Myeloma
Register for Updates
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
NCT05615623
Recruiting
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
04/28/2025
Locations: Sunnybrook Research Institute, Toronto, Ontario
Conditions: Brain Tumor
Register for Updates
AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793
Recruiting
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: Research Site, Duarte, California +85 locations
Conditions: B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL)
Register for Updates
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
NCT06453486
Recruiting
The goal of this clinical trial is to test the effect of high-dose radiation therapy after initial chemotherapy in patients with locally advanced pancreatic cancer. The main question it aims to answer is: • For patients with locally advanced pancreatic cancer that responded to initial chemotherapy (stayed stable or decreased in size), will high-dose RT (radiation therapy) contribute to improving treatment outcomes, enhancing quality of life, or increasing overall survival rates? Participants w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Conditions: Locally Advanced Pancreatic Adenocarcinoma
Register for Updates
Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer
NCT04931017
Recruiting
This phase II trial determines the effect of metformin extended release on the risk for developing lung cancer in overweight/obese patients that are at high-risk for developing lung cancer. Metformin is widely used to treat type II diabetes and has a long history of safety and minimal side effects. At similar dosage, the drug may have potential anti-cancer activity. Metformin use has been associated with improved survival in patients with non-small cell lung carcinoma, a specific type of lung ca... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
04/25/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, Colorado +3 locations
Conditions: Lung Carcinoma
Register for Updates
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
NCT05717166
Recruiting
This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease. Patients will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis3: histology (Group 1: hormone-sensitive prostate cancer, breast, or renal; Group 2: all others), and number of metastases (Group 1: 1-3; Group 2: 4-10... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: BC Cancer - Centre for the North, Prince George, British Columbia +3 locations
Conditions: Metastatic Tumor
Register for Updates
Physical Activity Program for TRD
NCT06404320
Recruiting
This is a pilot study examining the delivery of a remotely delivered, one-on-one, individualized physical activity (PA) program in adult participants with treatment-resistant depression (TRD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2025
Locations: St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario
Conditions: Treatment-resistant Depression, Major Depressive Disorder
Register for Updates
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099
Recruiting
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300 participants will be enrolled to continue receiving treatment with riliprubart. The duration of par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Investigational Site Number : 1240001, Gatineau, Quebec +2 locations
Conditions: Polyneuropathy, Inflammatory Demyelinating, Chronic
Register for Updates